News tagged with her2
Tumors with ALK rearrangements can harbor more mutations
The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung ...
Cancer
Apr 22, 2013 |
not rated yet |
0
Study suggests patients with lung cancer who carry specific HER2 mutations may benefit from certain anti-HER2 treatments
New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced ...
Cancer
Apr 22, 2013 |
not rated yet |
0
Scientists identify potential target to reduce progression of metastases
A team of researchers at the IRCM, led by Dr. Jean-François Côté, made an important discovery in breast cancer, which will published online this week by the scientific journal Proceedings of the National Academy of Sc ...
Cancer
Apr 15, 2013 |
5 / 5 (2) |
0
|
Researchers identify critical metabolic alterations in triple-negative breast cancer cells
Researchers at Fox Chase Cancer Center have identified a host of small molecules critical to metabolism in cells of triple-negative breast cancer—one of the least understood groups of breast cancer. These molecules, called ...
Cancer
Apr 09, 2013 |
not rated yet |
0
Omega-3 fatty acids more effective at inhibiting growth of triple-negative breast cancer
Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the proliferation, or growth in the number of cells, of triple-negative breast cancer cells more effectively ...
Cancer
Apr 09, 2013 |
4 / 5 (1) |
0
Scientists find promising new target for aggressive breast cancer
Women with triple-negative breast cancer are more likely to have high levels of the MET biomarker in their tumours, making it a good new target for cancer drugs according to research published in the British Jo ...
Cancer
Mar 20, 2013 |
not rated yet |
0
New research challenges notion of using Herceptin only for HER2-positive breast cancer
New research from the University of Michigan Comprehensive Cancer Center finds that the protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative – and that ...
Cancer
Feb 26, 2013 |
not rated yet |
0
|
Breast cancer gene provides vital clue to bowel cancer drug resistance
Having too many copies of a gene linked to breast cancer might be the reason why some bowel cancer patients fail to respond to certain targeted drugs, according to a study published in the British Journal of ...
Cancer
Feb 20, 2013 |
not rated yet |
0
|
Researchers discover biological diversity in triple-negative breast cancer
Triple-negative breast cancers are more biologically diverse than previously believed and classification should be expanded to reflect this heterogeneity, according to University of North Carolina researchers.
Cancer
Feb 13, 2013 |
not rated yet |
0
|
The HER2 paradox: HER2-positive stem cells found in HER2-negative breast cancer
A multicenter study led by researchers at UC Davis describes new, paradoxical characteristics of the most common type of breast cancer. The findings shed light on how the disease can evade treatment and could improve diagnosis ...
Cancer
Dec 14, 2012 |
5 / 5 (1) |
0
Delaying childbirth may reduce the risk of an aggressive form of breast cancer in younger women, study suggests
(Medical Xpress)—Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according ...
Cancer
Dec 12, 2012 |
not rated yet |
0
|
Existing drugs may help more breast cancer patients
More patients can benefit from highly effective breast cancer drugs that are already available, according to DNA sequencing studies by researchers at Washington University School of Medicine in St. Louis ...
Cancer
Dec 07, 2012 |
not rated yet |
0
Clinical trial hits new target in war on breast cancer
Breast cancers are defined by their drivers – estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer ...
Cancer
Dec 03, 2012 |
5 / 5 (2) |
0
|
Drug combination shrinks secondary brain tumours in breast cancer without substantial side effects of radiotherapy
The sizeable and increasing proportion of women with advanced breast cancer whose disease has spread to the brain could be effectively treated systemically with a combination of two drugs, sparing them the debilitating neurological ...
Cancer
Nov 01, 2012 |
5 / 5 (1) |
0
New findings on optimal duration of trastuzumab therapy for women with HER2+ early breast cancer
New studies that advance understanding of the optimal duration of therapy with the targeted cancer drug trastuzumab were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Cancer
Oct 01, 2012 |
not rated yet |
0
HER2/neu
HER2/neu (also known as ErbB-2) stands for "Human Epidermal growth factor Receptor 2" and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2/neu has also been designated as CD340 (cluster of differentiation 340) and p185. It is encoded by the ERBB2 gene.
For more information about HER2/neu, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
